A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4836-

  Flaherty, Keith T ^a   Schiller, Joan ^b   Schuchter, Lynn M ^a   Liu, Glenn ^b   Tuveson, David A ^c   Redlinger, Maryann ^a   Lathia, Chetan ^d   Xia, Chenghua ^d   Petrenciuc, Oana ^e   Hingorani, Sunil R ^f   Jacobetz, Michael A ^c   Van Belle, Patricia A ^a   Elder, David ^a   Brose, Marcia S ^a,g   Weber, Barbara L ^h   Albertini, Mark R ^b   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d BAYER CORPORATION   (United States)

^e Bayer Inc   (Canada)

^f Fred Hutchinson Cancer Research Center

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; PACLITAXEL; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; BIOPSY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BIOPSY; CARBOPLATIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; PYRIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 51049095131     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4123     Document Type: Article

References (32)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
2. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34.
3. Levy JB, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-0 human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006) [abstract]. AACR Meet Abstr 2006;2006:213-d-214.
4. Sharma A. Trivedi NR. Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21.
5. Strumberg D. Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.
6. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
8. Heim M, Sharifi M, Hilger RA, et al. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther 2003;41:616-7.
9. Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human nonsmall cell lung carcinoma. Cancer Chemother Pharmacol 2007;59:183-95.
10. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 2005;5:188-96
11. Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73.
12. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144 51.
13. Richly H, Kupsch P, Passage K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer Int J Clin Pharmacol Ther 2004;42:650-1.
14. Eisen T, Ahmad T Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
15. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma J Clin Oncol 1987;5:1232-9.
16. Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of Taxol in metastatic melanoma Cancer 1990;65: 2478-81.
17. Einzig Al, Hochster H, Wiernik PH, et al. A phase II study of Taxol in patients with malignant melanoma Invest New Drugs1991;9:59-64.
18. Aamdal S, Wolff I. Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994;30A:1061-4.
19. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995;13:2895-9.
20. Einzig Al, Schuchter LM, Recio A, et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 1996;13:111-7.
21. Zimpfer-Rechner C, Hofmann U, Figl R, et al Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003;13:531-6.
22. Hodi FS, Soiffer RJ, Clark J, et al. Phase II study of paclitaxel and carboplatin for malignant melanoma Am J Clin Oncol 2002;25:283-6.
23. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic meianoma. Cancer 2006 106:375-82.
24. Lathia C, Lettieri J, Cihon F, et al Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 2006;57:685-92.
25. Brose MS. VoIpe P, Feldman M, et al BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 2002:62:6997-7000
26. Kent LL. Hull-Campbell NE. Lau T, et al Character ization of novel inhibitors of cyclin-dependent kinases Biochem Biophys Res Commun 1999;260:768 74
27. Schiller JH, Harrington D, Belani CP. et al Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 2002;346:92-8.
28. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80
29. Moore M, Hirte HW, Siu L. et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006. administered for 28 days on, 7 days off in patients with advanced, refractory solid tumors Ann Oncol 2005;16:1688-94.
30. Agarwala SS, Keilholz U, Hogg DC, et al Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol ASCO Annu Meet Proc Part I 2007:25 8510 (Jun 20 Suppl).
31. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer Nature 2002:417 949-54.
32. Murphy DA, Makonnen S. Lassoued W. et al Inhibi tion of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006) Am J Pathol 2006;169:1875-85